Share Price and Basic Stock Data
Last Updated: January 17, 2026, 12:37 pm
| PEG Ratio | 1.33 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sun Pharmaceuticals Industries Ltd operates in the pharmaceutical sector and has demonstrated robust revenue growth over recent years. The company’s sales stood at ₹43,886 Cr for the fiscal year ending March 2023, reflecting a significant increase from ₹38,654 Cr in the previous fiscal year. In the subsequent fiscal year ending March 2024, sales are projected to rise further to ₹48,497 Cr, with the trailing twelve months (TTM) revenue reported at ₹54,964 Cr. Quarterly sales have shown a consistent upward trajectory, increasing from ₹10,952 Cr in September 2022 to ₹12,192 Cr in September 2023. This growth trend is indicative of strong demand for Sun Pharma’s products and effective market strategies, positioning it favorably within a competitive industry.
Profitability and Efficiency Metrics
Sun Pharmaceuticals has maintained healthy profitability margins, with a reported operating profit margin (OPM) of 31% as of the latest fiscal year. The net profit for the same period reached ₹10,485 Cr, showcasing an impressive net profit margin of approximately 20.88%. The company’s return on equity (ROE) stood at 16.9%, while return on capital employed (ROCE) was reported at 20.2%, both indicative of efficient use of capital. The interest coverage ratio (ICR) at 74.50x highlights the company’s ability to meet its interest obligations comfortably, which is significantly higher than typical sector ranges, suggesting strong financial health. However, fluctuations in quarterly net profit, as seen from ₹2,006 Cr in June 2023 to ₹3,125 Cr in September 2025, may warrant attention regarding operational consistency.
Balance Sheet Strength and Financial Ratios
Sun Pharmaceuticals’ balance sheet showcases solid financial health, with total assets reported at ₹91,908 Cr as of March 2025. The company’s reserves have grown to ₹77,580 Cr, reflecting a robust retention of earnings, while borrowings stood at ₹5,215 Cr, indicating a low leverage position. The debt-to-equity ratio is notably low at 0.02, underscoring the company’s conservative approach to financing. Additionally, Sun Pharma’s price-to-book value ratio of 5.77x suggests that the stock is trading at a premium compared to its book value, which stood at ₹301.00 per share. The current ratio of 2.89 indicates good short-term liquidity, ensuring that the company can meet its short-term liabilities without financial strain. These financial ratios position Sun Pharmaceuticals favorably against industry standards.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sun Pharmaceuticals reveals a stable ownership structure, with promoters holding 54.48% of the total shares. This significant stake reflects strong insider confidence in the company’s future performance. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 16.55% and 20.12% of the shares, respectively, indicating a diversified investor base. The number of shareholders has increased from 6,32,337 in December 2022 to 7,43,877 by September 2025, suggesting growing investor interest. However, the public holding has gradually decreased from 9.52% in December 2022 to 8.72% in September 2025, which may indicate a shift in investor sentiment. Overall, the current shareholding structure reflects a mix of institutional confidence and stable promoter support, vital for long-term growth.
Outlook, Risks, and Final Insight
Looking ahead, Sun Pharmaceuticals is well-positioned to capitalize on growth opportunities within the pharmaceutical industry, backed by strong revenue trends and solid profitability metrics. However, potential risks include fluctuations in raw material costs, regulatory challenges, and competitive pressures from both domestic and international players. The company’s ability to maintain operational efficiency and manage costs will be crucial in sustaining its growth trajectory. Additionally, as the market evolves, Sun Pharma must innovate and adapt its product offerings to meet changing consumer demands. Should the company successfully navigate these challenges, it could strengthen its market position significantly, leading to enhanced shareholder value over the long term. Overall, while the outlook remains positive, vigilant risk management will be essential for sustaining growth and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,989.74 Cr | 1,116.46 | 52.28 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10,952 | 11,241 | 10,931 | 11,941 | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 |
| Expenses | 7,996 | 8,237 | 8,129 | 8,609 | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 |
| Operating Profit | 2,957 | 3,004 | 2,802 | 3,332 | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 |
| OPM % | 27% | 27% | 26% | 28% | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% |
| Other Income | 85 | 174 | 202 | -118 | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 |
| Interest | 19 | 46 | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 |
| Depreciation | 610 | 660 | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 |
| Profit before tax | 2,412 | 2,471 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 |
| Tax % | 6% | 11% | 10% | 19% | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% |
| Net Profit | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 |
| EPS in Rs | 9.43 | 9.03 | 8.27 | 8.43 | 9.90 | 10.52 | 11.06 | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 |
Last Updated: December 29, 2025, 12:04 am
Below is a detailed analysis of the quarterly data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 14,478.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,851.00 Cr. (Jun 2025) to 14,478.00 Cr., marking an increase of 627.00 Cr..
- For Expenses, as of Sep 2025, the value is 9,951.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,550.00 Cr. (Jun 2025) to 9,951.00 Cr., marking an increase of 401.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 4,527.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,302.00 Cr. (Jun 2025) to 4,527.00 Cr., marking an increase of 225.00 Cr..
- For OPM %, as of Sep 2025, the value is 31.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 31.00%.
- For Other Income, as of Sep 2025, the value is 470.00 Cr.. The value appears strong and on an upward trend. It has increased from -354.00 Cr. (Jun 2025) to 470.00 Cr., marking an increase of 824.00 Cr..
- For Interest, as of Sep 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 75.00 Cr. (Jun 2025) to 100.00 Cr., marking an increase of 25.00 Cr..
- For Depreciation, as of Sep 2025, the value is 730.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 701.00 Cr. (Jun 2025) to 730.00 Cr., marking an increase of 29.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 4,168.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,173.00 Cr. (Jun 2025) to 4,168.00 Cr., marking an increase of 995.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Jun 2025) to 25.00%, marking a decrease of 2.00%.
- For Net Profit, as of Sep 2025, the value is 3,125.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,293.00 Cr. (Jun 2025) to 3,125.00 Cr., marking an increase of 832.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 13.00. The value appears strong and on an upward trend. It has increased from 9.50 (Jun 2025) to 13.00, marking an increase of 3.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16,080 | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 54,964 |
| Expenses | 9,078 | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,235 | 35,479 | 37,464 | 38,410 |
| Operating Profit | 7,003 | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,554 |
| OPM % | 44% | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% | 29% | 30% |
| Other Income | -1,968 | 283 | -42 | 610 | -135 | -258 | 382 | -3,449 | -3,505 | 459 | 865 | 1,444 | 517 |
| Interest | 44 | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 | 238 | 231 | 275 |
| Depreciation | 409 | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 | 2,557 | 2,575 | 2,724 |
| Profit before tax | 4,581 | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 | 13,752 | 14,071 |
| Tax % | 15% | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% | 13% | 20% | |
| Net Profit | 3,879 | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 10,485 |
| EPS in Rs | 15.17 | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 43.56 |
| Dividend Payout % | 10% | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% | 34% | 35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 41.17% | 3.32% | 38.67% | -67.60% | 26.20% | 30.05% | -45.54% | 49.16% | 151.20% | 12.89% | 14.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.85% | 35.35% | -106.27% | 93.80% | 3.85% | -75.59% | 94.71% | 102.03% | -138.31% | 1.21% |
Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 25% |
| 3 Years: | 21% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 1:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:02 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 18,318 | 25,431 | 32,742 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 | 77,580 |
| Borrowings | 2,561 | 8,996 | 8,497 | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | 3,274 | 2,362 | 5,215 |
| Other Liabilities | 8,009 | 14,089 | 13,948 | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,474 | 17,831 | 18,387 | 17,328 | 20,672 |
| Total Liabilities | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 103,706 |
| Fixed Assets | 6,817 | 12,682 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 | 33,371 |
| CWIP | 842 | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 | 1,355 |
| Investments | 2,786 | 2,716 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 | 19,543 |
| Other Assets | 18,650 | 31,286 | 35,550 | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 32,975 | 36,849 | 41,700 | 44,324 | 49,438 |
| Total Assets | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 103,706 |
Below is a detailed analysis of the balance sheet data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 240.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 240.00 Cr..
- For Reserves, as of Sep 2025, the value is 77,580.00 Cr.. The value appears strong and on an upward trend. It has increased from 71,978.00 Cr. (Mar 2025) to 77,580.00 Cr., marking an increase of 5,602.00 Cr..
- For Borrowings, as of Sep 2025, the value is 5,215.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,362.00 Cr. (Mar 2025) to 5,215.00 Cr., marking an increase of 2,853.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 20,672.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17,328.00 Cr. (Mar 2025) to 20,672.00 Cr., marking an increase of 3,344.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 103,706.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 91,908.00 Cr. (Mar 2025) to 103,706.00 Cr., marking an increase of 11,798.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 33,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 22,586.00 Cr. (Mar 2025) to 33,371.00 Cr., marking an increase of 10,785.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,355.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,644.00 Cr. (Mar 2025) to 1,355.00 Cr., marking a decrease of 5,289.00 Cr..
- For Investments, as of Sep 2025, the value is 19,543.00 Cr.. The value appears strong and on an upward trend. It has increased from 18,354.00 Cr. (Mar 2025) to 19,543.00 Cr., marking an increase of 1,189.00 Cr..
- For Other Assets, as of Sep 2025, the value is 49,438.00 Cr.. The value appears strong and on an upward trend. It has increased from 44,324.00 Cr. (Mar 2025) to 49,438.00 Cr., marking an increase of 5,114.00 Cr..
- For Total Assets, as of Sep 2025, the value is 103,706.00 Cr.. The value appears strong and on an upward trend. It has increased from 91,908.00 Cr. (Mar 2025) to 103,706.00 Cr., marking an increase of 11,798.00 Cr..
Notably, the Reserves (77,580.00 Cr.) exceed the Borrowings (5,215.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 5.00 | -1.00 | 0.00 | 1.00 | -5.00 | -4.00 | -2.00 | 5.00 | 9.00 | 5.00 | 10.00 | 13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 68 | 87 | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 | 91 |
| Inventory Days | 410 | 307 | 370 | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 | 348 |
| Days Payable | 174 | 178 | 207 | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 | 210 |
| Cash Conversion Cycle | 286 | 197 | 251 | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 | 228 |
| Working Capital Days | 71 | -7 | 37 | -4 | -31 | 31 | 51 | 51 | 47 | 40 | 55 | 65 |
| ROCE % | 34% | 23% | 18% | 20% | 10% | 10% | 10% | 13% | 17% | 16% | 17% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Value Fund | 15,507,434 | 4.7 | 2840.34 | N/A | N/A | N/A |
| ICICI Prudential Equity & Debt Fund | 13,476,970 | 5.01 | 2468.44 | 7,973,496 | 2025-12-08 02:56:21 | 69.02% |
| ICICI Prudential Large Cap Fund | 11,771,629 | 2.76 | 2156.09 | N/A | N/A | N/A |
| ICICI Prudential India Opportunities Fund | 7,527,584 | 4.06 | 1378.75 | 8,048,086 | 2025-12-15 02:23:09 | -6.47% |
| HDFC Balanced Advantage Fund | 6,784,634 | 1.15 | 1242.67 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 6,256,349 | 13.55 | 1145.91 | 6,556,349 | 2025-12-08 04:19:42 | -4.58% |
| HDFC Large Cap Fund | 6,054,009 | 2.73 | 1108.85 | N/A | N/A | N/A |
| ICICI Prudential Multi Asset Fund | 5,946,417 | 1.45 | 1089.15 | 6,284,904 | 2025-12-15 02:23:09 | -5.39% |
| ICICI Prudential ELSS Tax Saver Fund | 5,105,969 | 6.25 | 935.21 | N/A | N/A | N/A |
| ICICI Prudential Balanced Advantage Fund | 4,827,054 | 1.27 | 884.12 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 45.60 | 39.90 | 35.30 | 13.60 | 12.10 |
| Diluted EPS (Rs.) | 45.60 | 39.90 | 35.30 | 13.60 | 12.10 |
| Cash EPS (Rs.) | 56.50 | 50.87 | 46.22 | 23.13 | 18.19 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 301.00 | 265.36 | 247.22 | 212.84 | 206.23 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 301.00 | 265.36 | 247.22 | 212.84 | 206.23 |
| Revenue From Operations / Share (Rs.) | 219.14 | 202.13 | 182.91 | 161.11 | 139.62 |
| PBDIT / Share (Rs.) | 71.84 | 59.92 | 51.19 | 47.18 | 38.87 |
| PBIT / Share (Rs.) | 61.11 | 49.27 | 40.64 | 38.24 | 30.20 |
| PBT / Share (Rs.) | 57.32 | 46.21 | 39.21 | 18.68 | 11.67 |
| Net Profit / Share (Rs.) | 45.76 | 40.21 | 35.68 | 14.20 | 9.52 |
| NP After MI And SOA / Share (Rs.) | 45.55 | 39.91 | 35.32 | 13.64 | 12.10 |
| PBDIT Margin (%) | 32.78 | 29.64 | 27.98 | 29.28 | 27.84 |
| PBIT Margin (%) | 27.88 | 24.37 | 22.22 | 23.73 | 21.63 |
| PBT Margin (%) | 26.15 | 22.86 | 21.43 | 11.59 | 8.35 |
| Net Profit Margin (%) | 20.88 | 19.89 | 19.50 | 8.81 | 6.82 |
| NP After MI And SOA Margin (%) | 20.78 | 19.74 | 19.30 | 8.46 | 8.66 |
| Return on Networth / Equity (%) | 15.13 | 15.04 | 15.13 | 6.81 | 6.24 |
| Return on Capital Employeed (%) | 19.83 | 17.26 | 16.02 | 17.44 | 14.06 |
| Return On Assets (%) | 11.86 | 11.20 | 10.49 | 4.68 | 4.29 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.02 | 0.04 | 0.11 | 0.01 | 0.07 |
| Asset Turnover Ratio (%) | 0.59 | 0.58 | 0.58 | 0.56 | 0.49 |
| Current Ratio (X) | 2.89 | 2.56 | 2.00 | 2.04 | 1.89 |
| Quick Ratio (X) | 2.33 | 1.98 | 1.48 | 1.51 | 1.33 |
| Inventory Turnover Ratio (X) | 5.23 | 4.76 | 0.79 | 0.78 | 0.72 |
| Dividend Payout Ratio (NP) (%) | 33.06 | 30.26 | 29.73 | 65.96 | 53.68 |
| Dividend Payout Ratio (CP) (%) | 26.76 | 23.88 | 22.89 | 39.85 | 31.28 |
| Earning Retention Ratio (%) | 66.94 | 69.74 | 70.27 | 34.04 | 46.32 |
| Cash Earning Retention Ratio (%) | 73.24 | 76.12 | 77.11 | 60.15 | 68.72 |
| Interest Coverage Ratio (X) | 74.50 | 60.29 | 71.40 | 88.88 | 65.95 |
| Interest Coverage Ratio (Post Tax) (X) | 51.39 | 43.53 | 51.77 | 63.60 | 47.60 |
| Enterprise Value (Cr.) | 407192.46 | 384570.80 | 239622.86 | 218440.19 | 143296.74 |
| EV / Net Operating Revenue (X) | 7.74 | 7.93 | 5.46 | 5.65 | 4.28 |
| EV / EBITDA (X) | 23.62 | 26.75 | 19.51 | 19.30 | 15.36 |
| MarketCap / Net Operating Revenue (X) | 7.92 | 8.02 | 5.37 | 5.68 | 4.28 |
| Retention Ratios (%) | 66.93 | 69.73 | 70.26 | 34.03 | 46.31 |
| Price / BV (X) | 5.77 | 6.11 | 4.21 | 4.57 | 3.09 |
| Price / Net Operating Revenue (X) | 7.92 | 8.02 | 5.37 | 5.68 | 4.28 |
| EarningsYield | 0.02 | 0.02 | 0.03 | 0.01 | 0.02 |
After reviewing the key financial ratios for Sun Pharmaceuticals Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 45.60. This value is within the healthy range. It has increased from 39.90 (Mar 24) to 45.60, marking an increase of 5.70.
- For Diluted EPS (Rs.), as of Mar 25, the value is 45.60. This value is within the healthy range. It has increased from 39.90 (Mar 24) to 45.60, marking an increase of 5.70.
- For Cash EPS (Rs.), as of Mar 25, the value is 56.50. This value is within the healthy range. It has increased from 50.87 (Mar 24) to 56.50, marking an increase of 5.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 301.00. It has increased from 265.36 (Mar 24) to 301.00, marking an increase of 35.64.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 301.00. It has increased from 265.36 (Mar 24) to 301.00, marking an increase of 35.64.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 219.14. It has increased from 202.13 (Mar 24) to 219.14, marking an increase of 17.01.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 71.84. This value is within the healthy range. It has increased from 59.92 (Mar 24) to 71.84, marking an increase of 11.92.
- For PBIT / Share (Rs.), as of Mar 25, the value is 61.11. This value is within the healthy range. It has increased from 49.27 (Mar 24) to 61.11, marking an increase of 11.84.
- For PBT / Share (Rs.), as of Mar 25, the value is 57.32. This value is within the healthy range. It has increased from 46.21 (Mar 24) to 57.32, marking an increase of 11.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 45.76. This value is within the healthy range. It has increased from 40.21 (Mar 24) to 45.76, marking an increase of 5.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 45.55. This value is within the healthy range. It has increased from 39.91 (Mar 24) to 45.55, marking an increase of 5.64.
- For PBDIT Margin (%), as of Mar 25, the value is 32.78. This value is within the healthy range. It has increased from 29.64 (Mar 24) to 32.78, marking an increase of 3.14.
- For PBIT Margin (%), as of Mar 25, the value is 27.88. This value exceeds the healthy maximum of 20. It has increased from 24.37 (Mar 24) to 27.88, marking an increase of 3.51.
- For PBT Margin (%), as of Mar 25, the value is 26.15. This value is within the healthy range. It has increased from 22.86 (Mar 24) to 26.15, marking an increase of 3.29.
- For Net Profit Margin (%), as of Mar 25, the value is 20.88. This value exceeds the healthy maximum of 10. It has increased from 19.89 (Mar 24) to 20.88, marking an increase of 0.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.78. This value exceeds the healthy maximum of 20. It has increased from 19.74 (Mar 24) to 20.78, marking an increase of 1.04.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.13. This value is within the healthy range. It has increased from 15.04 (Mar 24) to 15.13, marking an increase of 0.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.83. This value is within the healthy range. It has increased from 17.26 (Mar 24) to 19.83, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 11.86. This value is within the healthy range. It has increased from 11.20 (Mar 24) to 11.86, marking an increase of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.58 (Mar 24) to 0.59, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.89. This value is within the healthy range. It has increased from 2.56 (Mar 24) to 2.89, marking an increase of 0.33.
- For Quick Ratio (X), as of Mar 25, the value is 2.33. This value exceeds the healthy maximum of 2. It has increased from 1.98 (Mar 24) to 2.33, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.23. This value is within the healthy range. It has increased from 4.76 (Mar 24) to 5.23, marking an increase of 0.47.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 33.06. This value is within the healthy range. It has increased from 30.26 (Mar 24) to 33.06, marking an increase of 2.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.76. This value is within the healthy range. It has increased from 23.88 (Mar 24) to 26.76, marking an increase of 2.88.
- For Earning Retention Ratio (%), as of Mar 25, the value is 66.94. This value is within the healthy range. It has decreased from 69.74 (Mar 24) to 66.94, marking a decrease of 2.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.24. This value exceeds the healthy maximum of 70. It has decreased from 76.12 (Mar 24) to 73.24, marking a decrease of 2.88.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 74.50. This value is within the healthy range. It has increased from 60.29 (Mar 24) to 74.50, marking an increase of 14.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 51.39. This value is within the healthy range. It has increased from 43.53 (Mar 24) to 51.39, marking an increase of 7.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 407,192.46. It has increased from 384,570.80 (Mar 24) to 407,192.46, marking an increase of 22,621.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.74. This value exceeds the healthy maximum of 3. It has decreased from 7.93 (Mar 24) to 7.74, marking a decrease of 0.19.
- For EV / EBITDA (X), as of Mar 25, the value is 23.62. This value exceeds the healthy maximum of 15. It has decreased from 26.75 (Mar 24) to 23.62, marking a decrease of 3.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.92. This value exceeds the healthy maximum of 3. It has decreased from 8.02 (Mar 24) to 7.92, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 66.93. This value is within the healthy range. It has decreased from 69.73 (Mar 24) to 66.93, marking a decrease of 2.80.
- For Price / BV (X), as of Mar 25, the value is 5.77. This value exceeds the healthy maximum of 3. It has decreased from 6.11 (Mar 24) to 5.77, marking a decrease of 0.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.92. This value exceeds the healthy maximum of 3. It has decreased from 8.02 (Mar 24) to 7.92, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharmaceuticals Industries Ltd:
- Net Profit Margin: 20.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.83% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.13% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 51.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.33
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.7 (Industry average Stock P/E: 52.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dilip S Shanghvi | Chairman & Managing Director |
| Mr. Aalok D Shanghvi | Whole Time Director & COO |
| Ms. Vidhi D Shanghvi | Whole Time Director |
| Mr. Sudhir V Valia | Non Exe.Non Ind.Director |
| Dr. Pawan Goenka | Lead Independent Director |
| Mr. Rama Bijapurkar | Independent Director |
| Mr. Gautam Doshi | Independent Director |
| Mr. Rolf Hoffmann | Independent Director |
FAQ
What is the intrinsic value of Sun Pharmaceuticals Industries Ltd?
Sun Pharmaceuticals Industries Ltd's intrinsic value (as of 17 January 2026) is ₹1935.78 which is 15.98% higher the current market price of ₹1,669.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹4,00,425 Cr. market cap, FY2025-2026 high/low of ₹1,851/1,547, reserves of ₹77,580 Cr, and liabilities of ₹103,706 Cr.
What is the Market Cap of Sun Pharmaceuticals Industries Ltd?
The Market Cap of Sun Pharmaceuticals Industries Ltd is 4,00,425 Cr..
What is the current Stock Price of Sun Pharmaceuticals Industries Ltd as on 17 January 2026?
The current stock price of Sun Pharmaceuticals Industries Ltd as on 17 January 2026 is ₹1,669.
What is the High / Low of Sun Pharmaceuticals Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sun Pharmaceuticals Industries Ltd stocks is ₹1,851/1,547.
What is the Stock P/E of Sun Pharmaceuticals Industries Ltd?
The Stock P/E of Sun Pharmaceuticals Industries Ltd is 34.7.
What is the Book Value of Sun Pharmaceuticals Industries Ltd?
The Book Value of Sun Pharmaceuticals Industries Ltd is 324.
What is the Dividend Yield of Sun Pharmaceuticals Industries Ltd?
The Dividend Yield of Sun Pharmaceuticals Industries Ltd is 0.96 %.
What is the ROCE of Sun Pharmaceuticals Industries Ltd?
The ROCE of Sun Pharmaceuticals Industries Ltd is 20.2 %.
What is the ROE of Sun Pharmaceuticals Industries Ltd?
The ROE of Sun Pharmaceuticals Industries Ltd is 16.9 %.
What is the Face Value of Sun Pharmaceuticals Industries Ltd?
The Face Value of Sun Pharmaceuticals Industries Ltd is 1.00.